MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 11, 2008; DOI: 10.1124/mol.108.045963


0026-895X/08/7306-1776-1784$20.00
Mol Pharmacol 73:1776-1784, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.045963v1
73/6/1776    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Madoux, F.
Right arrow Articles by Hodder, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Madoux, F.
Right arrow Articles by Hodder, P.

Potent, Selective and Cell Penetrant Inhibitors of SF-1 by Functional Ultra-High-Throughput Screening

Franck Madoux, Xiaolin Li, Peter Chase, Gina Zastrow, Michael D. Cameron, Juliana J. Conkright, Patrick R. Griffin, Scott Thacher, and Peter Hodder

Scripps Research Molecular Screening Center (F.M., P.C., P.R.G., P.H.), Translational Research Institute (F.M., P.C., G.Z., M.D.C., J.C., P.R.G., P.S.H.), and Molecular Therapeutics (P.R.G., P.H.), The Scripps Research Institute, Scripps Florida, Jupiter, Florida; and Orphagen Pharmaceuticals, San Diego California (X.L., S.T.)

The steroidogenic factor 1 (SF-1, also known as NR5A1) is a transcription factor belonging to the nuclear receptor superfamily. Whereas most of the members of this family have been extensively characterized, the therapeutic potential and pharmacology of SF-1 still remains elusive. Described here is the identification and characterization of selective inhibitory chemical probes of SF-1 by a rational ultra-high-throughput screening (uHTS) strategy. A set of 64,908 compounds from the National Institute of Health's Molecular Libraries Small Molecule Repository was screened in a transactivation cell-based assay employing a chimeric SF-1 construct. Two analogous isoquinolinones, ethyl 2-[2-[2-(2,3-dihydro-1,4-benzodioxin-7-ylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate (SID7969543) and ethyl 2-[2-[2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate and (SID7970631), were identified as potent submicromolar inhibitors, yielding IC50 values of 760 and 260 nM. The compounds retained their potency in a more physiologic functional assay employing the full-length SF-1 protein and its native response element, yielding IC50 values of 30 and 16 nM, respectively. The selectivity of these isoquinolinones was confirmed via transactivation-based functional assays for RAR-related orphan receptor A (RORA), Herpes simplex virus transcriptional activator protein Vmw65 (VP16), and liver receptor homolog 1 (LRH-1). Their cytotoxicity, solubility, permeability and metabolic stability were also measured. These isoquinolinones represent valuable chemical probes to investigate the therapeutic potential of SF-1.


Received February 1, 2008; accepted March 10, 2008

Address correspondence to: Prof. Peter Hodder, Director and Head, HTS Lead Identification Department, Scripps Florida, 5353 Parkside Drive RFA-6, Jupiter, FL 33458-2906. E-mail: hodderp{at}scripps.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics